OnCusp Therapeutics

OnCusp Therapeutics is a global biopharmaceutical company focused on transforming cutting-edge preclinical oncology innovations into clinically validated treatments for cancer patients worldwide. Co-founded by a team of accomplished veterans with expertise in building biotech startups, leading successful preclinical and clinical programs, and establishing global partnerships, OnCusp prioritizes accelerating the development of globally competitive oncology assets. They cultivate a culture rooted in medical innovation, emphasizing precise strategies and forging win-win partnerships. The company prioritizes honesty and transparency, striving to improve patient outcomes through a capital-efficient model, rigorous clinical trials, and a global licensing network.

OnCusp operates a unique business model, focusing on the high-risk, high-reward stage of drug development between preclinical candidate (PCC) and proof of concept (POC). They acquire global or overseas rights to PCC-stage assets, conduct clinical trials primarily in the US, and seek out-licensing partnerships with multinational pharmaceutical companies to advance promising drug candidates towards commercialization. The company prides itself on its global DNA, with a diverse team and global drug development expertise, ensuring their pipeline assets are developed for a worldwide market.

OnCusp Therapeutics is a global biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. They focus on the crucial phase of drug development where the risk is high but the potential reward is even greater, partnering with biotechnology firms, pharmaceutical companies, and academic researchers to accelerate the development of first-in-class or global top 3 preclinical assets. Their unique business model combines their deep expertise in clinical development with a robust global network, allowing them to quickly achieve clinical proof of concept and then license out these promising therapies to a broader audience.

OnCusp Therapeutics cultivates a culture rooted in medical innovation and a commitment to societal betterment. They prioritize precise, goal-oriented strategies while fostering win-win partnerships built on honesty and transparency. This culture values agility and accountability, encouraging calculated risks and leveraging collective experience to seize transformative opportunities. Their emphasis on fairness and equitable risk-sharing ensures strong partnerships that ultimately prioritize improving patient outcomes.

OnCusp Therapeutics prioritizes diversity, equity, and inclusion by fostering a global team with various backgrounds and perspectives. Their open corporate culture encourages open debates and idea sharing, leading to a more comprehensive view when making decisions. This diverse and inclusive environment allows them to tap into a wide range of talents and experiences, driving innovation and creating a more equitable and thriving company.